Reprint

Potential Anti-SARS-CoV-2 Molecular Strategies

Edited by
March 2023
254 pages
  • ISBN978-3-0365-6963-5 (Hardback)
  • ISBN978-3-0365-6962-8 (PDF)

This is a Reprint of the Special Issue Potential Anti-SARS-CoV-2 Molecular Strategies that was published in

Chemistry & Materials Science
Medicine & Pharmacology
Summary

Herein we describe some molecular aspects of the recent anti-COVID-19 research, including some approaches making use of natural remedies, especially from medicinal plants, in silico methods, and different experimental procedures that led to the discovery of novel targets of SARS-CoV-2 and consequently novel potential COVID-19 therapeutics. COVID-19 vaccines also find mention in this book with also a description of some adverse effects reported in some cases. Considering that the different beta coronaviruses present certain conserved biomolecular mechanisms and, thus, some common therapeutic targets, finding effective therapies for a specific member of their family (such as SARS-CoV, SARS-CoV-2, and MERS-CoV) even in a scenario of a reduced impact at the time of the related disease on humankind is still relevant as it could offer or inspire efficacious therapeutic strategies not only in the context of novel pathogenic mutations of the already known beta coronaviruses, but also when future zoonoses caused by other beta coronaviruses will emergence, which is not unlikely to occur in the current world where the interactions between humans and wildlife are made more and more frequent due to the growing loss of intact ecosystems worldwide.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
coronavirus infections; pandemics; natural compounds; clove; Syzygium aromaticum; eugenol; eugeniin; SARS-CoV-2; COVID-19; phytochemicals; herbal medicine; catechin; polyphenol; SARS-CoV-2; tea leaf extract; theaflavin; virucidal activity; MERS-CoV; S1-NTD; pharmacophore modeling; ADME; quantum mechanical calculation; DFT; FMO; MM/GBSA; molecular docking; Molecular Dynamics Simulation; HOMO; LUMO; COVID-19; COVID-19 vaccine; disseminated intravascular coagulation; heparin induced thrombocytopenia; platelet factor 4; thrombosis; thrombotic thrombo-cytopenic purpura; vaccine induced thrombocytopenia and thrombosis; disinfectants; ethanol; hand hygiene; ozonated water; SARS-CoV-2; slightly acidic electrolyzed water; virucidal activity; virucidal mechanism; SARS-CoV-2; coronavirus; renal disease; nephrotoxicity; reno-protective effect; green tea; epigallocatechin-3-gallate (EGCG); flavonoids; natural products; medicinal plant; COVID-19; natural products; SARS-Cov-2 nsp10; structural similarity; fingerprint; molecular docking; ADMET; toxicity; DFT; SARS-CoV-2; main protease; triazole; docking; MD simulation; drug; COVID-19; proteomic; vaccine; immunology; biomarker; COVID-19; cheminformatics; molecular docking; phytocompounds; systems pharmacology; anti-COVID-19; drug repositioning; molecular docking; molecular dynamic simulations; binding free energy; signal peptide; RBD protein; secretion; mutant; SARS-CoV-2; nucleocapsid or nucleoprotein; SARS-CoV-2; structure-based drug discovery; alphafold model and molecular dynamics; neuroinflammation; brain fog; neuropeptides; neurotransmission; metabolism; NSAIDs; COVID-19; SARS-CoV-2; inflammation; ketoprofen; n/a